Based on landmark developmental biology research at the University of California, Irvine, AMP-601 delivers a recombinant version of SCUBE3—a key signaling protein identified as “nature’s potent activator of new hair growth”. In preclinical testing, delivering this biological signal directly into the skin successfully reactivated sleeping hair roots and triggered robust new hair fiber production, paving the way for a novel class of regenerative hair loss therapies.
What Is It and How Does It Work?
AMP-601 is an investigational biological treatment developed by Amplifica Holdings Group. It delivers a lab-engineered version of SCUBE3 (Signal peptide-CUB-EGF-like domain-containing protein 3), a signaling molecule naturally produced inside healthy hair roots.
It works through a precise biological process called Recombinant SCUBE3 Paracrine Signaling and Stem Cell Activation:
-
The Master Messenger: Deep inside every healthy hair follicle, specialized “control cells” called dermal papilla cells send chemical instructions to neighboring hair stem cells. SCUBE3 is the primary messenger protein responsible for telling those stem cells to wake up and divide.
-
The Communication Breakdown: In pattern baldness and age-related hair thinning, dermal papilla cells become sluggish and stop producing enough SCUBE3. Without this signal, hair follicle stem cells remain trapped in a dormant resting (telogen) state, causing the follicle to shrink.
-
Restoring the Signal: AMP-601 delivers concentrated SCUBE3 directly to the follicle microenvironment. The protein binds to specific cell surface receptors (activating essential Hedgehog and Wnt signaling pathways), effectively “flipping the switch” that forces resting stem cells to re-enter their active growth (anagen) phase and begin producing thick hair fibers.
Because AMP-601 utilizes a natural human signaling protein rather than synthetic hormone blockers, it works entirely independently of testosterone and DHT, carrying zero risk of systemic sexual or hormonal side effects.
The Science: Unlocking “Nature’s Potent Activator” in Preclinical Testing
The scientific foundation of AMP-601 stems from research led by Dr. Maksim Plikus, Professor of Developmental and Cell Biology at UC Irvine and Chief Scientific Officer of Amplifica.
-
Identifying the Activation Key: Researchers isolated SCUBE3 after discovering that hyper-active dermal signaling molecules were capable of forcing dormant hair follicles to grow long, thick hair fibers.
-
Robust Anagen Induction: In preclinical animal and tissue models, micro-injecting recombinant SCUBE3 (AMP-601) acted as a potent catalyst, driving dormant hair follicles into active anagen growth far more rapidly than untreated control groups.
-
Targeted Dermal Papilla Stimulation: Molecular analysis confirmed that SCUBE3 specifically acts on dermal papilla and epithelial stem cell receptors, restoring the natural biological cross-talk required for robust hair shaft creation.
“Our research shows that SCUBE3 is nature’s potent activator of new hair growth, warranting further work on its biology and practical applications… This nature-inspired scientific approach uses a molecular mechanism that regrows natural hair.” — Dr. Maksim Plikus, Chief Scientific Officer at Amplifica and Professor of Developmental and Cell Biology at UC Irvine.
When Will It Be Available?
-
Current Stage: AMP-601 is currently in preclinical development and IND-enabling studies at Amplifica Holdings Group.
-
Timeline: Amplifica is prioritizing its lead clinical candidate (AMP-303) while preparing AMP-601 for initial human safety trials. If upcoming Phase 1/2 human clinical trials confirm safety and hair regrowth efficacy, AMP-601 is projected to reach medical centers and specialty clinics by 2029 or 2030.
Read next
Whats the best shampoo for hair loss?
How you can benefit from this treatment now
While AMP-601 completes its preclinical development, you can take practical steps today based on SCUBE3 and paracrine signaling science:
-
Support Dermal Papilla Signaling Naturally: Research proves that SCUBE3 works alongside the Wnt signaling pathway. Clinical treatments such as microneedling (derma-stamping) and Low-Level Laser Therapy (LLLT) are scientifically proven to induce mild tissue response signals that naturally upregulate local Wnt and growth factor signaling in dermal papilla cells.
-
Explore Active Injections from the Same Pipeline: Amplifica’s lead candidate, AMP-303, operates on complementary signaling pathways (targeting osteopontin and CD44) and has already demonstrated statistically significant hair count increases in human Phase 1 trials. You can track Amplifica’s clinical updates on ClinicalTrials.gov to monitor upcoming trial enrollments.
-
Avoid Unregulated “Growth Factor” Products: Medical experts caution against purchasing unauthorized, over-the-counter serums claiming to contain SCUBE3. Recombinant proteins require strict pharmaceutical-grade synthesis, stabilization, and sterile delivery systems to remain active and safe for skin application.
Sources: